Integrating Molecular Profiling and HER2-Targeted Therapies for NSCLC: Best Practices for Testing and Developing Treatment Plans in the Community Setting

Friday, June 5, 2026

12:00 p.m. – 1:00 p.m. ET

Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.

PRESENTING FACULTY

Melina E. Marmarelis, MD
Medical Director, Penn Mesothelioma Program
Assistant Professor of Medicine, Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

PROGRAM OVERVIEW

This TeleECHO Series explores the distinctions between different HER2 alterations in NSCLC patients, the associated disease burden, molecular profiling recommendations, challenges faced in the community setting, and the importance of sustaining a multidisciplinary team approach that aligns specialties to deliver coordinated care for NSCLC patients with pathogenically active HER2 mutations. Attendees will review the latest FDA approvals, specifically the recent introduction of new, oral HER2 tyrosine kinase inhibitors, that are rapidly changing the landscape of HER2 targeted therapies, to guide the development of personalized treatment plans and improve overall outcomes for patients with HER2-mutant NSCLC.

TARGET AUDIENCE

This activity is designed to meet the educational needs of community clinicians involved in the evaluation and management of patients with lung cancer, including oncologists, molecular pathologists, pulmonologists, radiologists, thoracic surgeons, and advanced practice providers (eg, oncology nurses, pharmacists, nurse practitioners).

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Evaluate different HER2 alterations, their prevalence, affected patient populations, and the burden of disease for HER2-mutant NSCLC
  • Describe best practices for molecular profiling in NSCLC, how to interpret results for HER2, and the treatment implications for test results
  • Appraise the clinical data for current and emerging HER2-targeted therapies to develop multidisciplinary treatment strategies for HER2-mutant NSCLC

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education (CE) for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

AAPA CREDIT DESIGNATION STATEMENT – LIVE

Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

ACCME INNOVATION PARTNER DISCLAIMER

Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Ophthalmologist-in-Chief
Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX

Search

[divi_global_search_form]

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for retinopathy of prematurity (ROP). Click on one of the options below to learn more about ROP.

Patient Toolkit

Patient Toolkit

Read more

What exactly is NSCLC?

What exactly is NSCLC?

Read more

What symptoms can NSCLC cause?

What symptoms can NSCLC cause?

Read more

How is NSCLC treated according to staging?

How is NSCLC treated according to staging?

Read more

How is early NSCLC treated with surgery or SBRT?

How is early NSCLC treated with surgery or SBRT?

Read more

When is chemotherapy used in NSCLC?

When is chemotherapy used in NSCLC?

Read more

When is radiation used in NSCLC?

When is radiation used in NSCLC?

Read more

When is immunotherapy used in NSCLC?

When is immunotherapy used in NSCLC?

Read more

When is targeted therapy used in NSCLC?

When is targeted therapy used in NSCLC?

Read more

Patient Journey

Patient Journey

Read more

Online resources

Online resources

Read more
This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | ROP Relief | All Rights Reserved | Website by Divigner